Search

Your search keyword '"Pavel Bogomolov"' showing total 9 results
Start Over Author "Pavel Bogomolov"
9 results on '"Pavel Bogomolov"'

1. Global multi-societies endorsement of the MAFLD definition

Author

Mohamed Alboraie, Tawesak Tanwandee, Xiaoyuan Xu, Dafina Nikolova, Enrique Carrera Estupiñan, Hasmik Ghazinyan, Sameer Alawadhi, Ponsiano Ocama, Gulnara Aghayeva, Alejandro Piscoya, Taghreed Farahat, Pramendra Prasad, Cosmas Rinaldi Adithya Lesmana, Shashank R Joshi, Said Al-Busafi, Vladimir Milivojevic, Violet Kayamba, Yeong Yeh Lee, Shahinul Alam, Chengwei Tang, Wei-Fen Xie, Moutaz Derbala, Yuemin Nan, Dennis Ndububa, Hongting Zheng, Jiajun Zhao, Nawal Alkhalidi, Yahya Ghanem, Phunchai Charatcharoenwitthaya, Mamun Mahtab, Nagwa N. Hegazy, Edford Sinkala, Cecil Kwaku Dovia, Moussa Ali Mahamat, Mortada El-Shabrawi, Dao Viet Hang, Shlomo Vinker, Bilal Hotayt, Mohammed Tahiri, Pavel Bogomolov, Nawal Afredj, Inass Shaltout, Reda Elwakil, Abd Elkhalek Hamed, Lubna Kamani, Maheeba Abdulla, Constant Assi, Oidov Baatarkhuu, Munira Al Tarrah, Yousef Ajlouni, Bounena Abidine, Christopher Muñoz, Mohammad Ali, Emad Salama, Abdelaziz Elamin, Iqbal Ahmad Memon, Aram Mirijanyan, Sajjad Jamil, Alexander V. Nersesov, Nseabasi Ekanem, Waseem Hamoudi, Bisi Bright, Teresa Casanovas, Ewaoche Itodo, Esther A Torres, Maja Karin, Enver Zerem, Svetlana Turcan, Audrius Dulskas, Iulianna Lupasco, Alina Jucov, Christian Tzeuton, Roger Sombie, Kateryna Lapshyna, Andrriy Dorofeyev, Yaw A Awuku, Hilal Ünalmış Duda, Rijimra Ande, Nehal El Koofy, Naglaa Kamal, Ziyan Pan, Angela Peltec, Liang Qiao, Andry Lalaina Rinà Rakotozafindrabe, Ahmed Salama, Reham Soliman, Badre Wafaa, Marinela Debu, Eileen A Micah, Gamal Shiha, Mohammed Eslam, and Yasser Fouad

Subjects
Specialties of internal medicine, RC581-951
Published
2024
Full Text
View/download PDF

2. The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)

Author

María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, Alma Keco-Huerga, Luis Bujanda, Alfredo J. Lucendo, Luis Rodrigo, Dino Vaira, Luis Fernández-Salazar, Jose M. Huguet, Jorge Pérez-Lasala, Natasa Brglez Jurecic, Galina Fadeenko, Jesús Barrio, Miguel Areia, Juan Ortuño, Rinaldo Pellicano, Marcis Leja, Javier Molina-Infante, Pavel Bogomolov, Sergey Alekseenko, Manuel Domínguez-Cajal, Judith Gómez-Camarero, Vassiliki Ntouli, Samuel J. Martínez-Domínguez, Rafael Ruiz-Zorrilla, Oscar Núñez, Aiman Silkanovna Sarsenbaeva, Pedro Almela, Perminder Phull, Marta Espada, Ignasi Puig, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, and on behalf of the Hp-EuReg Investigators

Subjects
statins, Helicobacter pylori, treatment, Therapeutics. Pharmacology, RM1-950
Abstract

Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1–1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59–0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4–2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3–5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

Published
2021
Full Text
View/download PDF

4. Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study

Author

Heiner Wedemeyer, Soo Aleman, Maurizia Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Dmitry Manuilov, Vithika Suri, Qi An, John Flaherty, Anu Osinusi, JulianSchulze zur Wiesch, Markus Cornberg, Stefan Zeuzem, and Pietro Lampertico

Published
2023
Full Text
View/download PDF

5. 135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE A LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Olga P. Nyssen, Laimas Jonaitis, Ángeles Pérez-Aísa, Dino Vaira, Giulia Fiorini, Ilaria Maria Saracino, Bojan Tepes, Dmitry Bordin, Alma Keco- Huerga, Manuel Castro-Fernández, Alfredo Lucendo, Liudmila Vologzhanina, Luis Bujanda, Natasa Brglez Jurecic, Maja Denkovski, Angel Lanas, Samuel Martínez-Dominguez, Enrique Alfaro, Marcis Leja, Renate Bumane, Emin Mammadov, Gulustan Babayeva, Umud Mahmudov, María Caldas, Luis Rodrigo, Frode Lerang, Galyna Fadieienko, Rustam Abdulkhakov, Jose María Huguet Malavés, Oleg Zaytsev, Tatiana Ilchishina, Luis Fernández-Salazar, Noelia Alcaide, Benito Velayos, Aiman Silkanovna Sarsenbaeva, Igor Bakulin, Antonietta G. Gravina, Marco Romano, Mónica Perona, Sergey Alekseenko, Jesús Barrio, Miguel Areia, Óscar Nuñez, Pavel Bogomolov, Blas José Gómez Rodríguez, Manuel Dominguez- Cajal, Judith Gomez Camarero, Manuel Jiménez Moreno, Sotirios Georgopoulos, Pedro Almela Notari, Ante Tonkic, Rinaldo Pellicano, Halis Simsek, Lumír Kunovský, Antonio Gasbarrini, Jose Maria Botargues Bote, Gyorgy M Buzas, Miguel Fernández-Bermejo, Perminder Phull, Marino Venerito, Peter Malfertheiner, Rosa Rosania, Alexander Link, Eduardo Iyo, Juozas Kupinskas, Oleg Shvets, Ricardo Marcos Pinto, Theodore Rokkas, Ilkay Simsek, Sinead Smith, Doron Boltin, Dominique Lamarque, Daniela Dobru, Wojciech Marlicz, Vladimir Milivojevic, Lyudmila Boyanova, Vincent Lamy, Michael Doulberis, Peter Bytzer, Lisette Capelle, Oleksiy Gridnyev, Ari Ristimaki, Anna Cano-Català, Ignasi Puig, Francis Mégraud, Colm O’Morain, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023
Full Text
View/download PDF

6. S1179 Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study

Author

Stacey Lee, Heiner Wedemeyer, Soo Aleman, Maurizia Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Dmitry Manuilov, Vithika Suri, Qi An, John F. Flaherty, Anu Osinusi, Julian Schulze zur Wiesch, Markus Cornberg, Stefan Zeuzem, and Pietro Lampertico

Subjects
Hepatology, Gastroenterology
Published
2022
Full Text
View/download PDF

7. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Author

Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, Antje Blank, Natalia Voronkova, Tatiana Stepanova, Olga Sagalova, Vladimir Chulanov, Marina Osipenko, Viacheslav Morozov, Natalia Geyvandova, Snezhana Sleptsova, Igor G Bakulin, Ilsiyar Khaertynova, Marina Rusanova, Anita Pathil, Uta Merle, Birgit Bremer, Lena Allweiss, Florian A Lempp, Kerstin Port, Mathias Haag, Matthias Schwab, Julian Schulze zur Wiesch, Markus Cornberg, Walter E Haefeli, Maura Dandri, Alexander Alexandrov, and Stephan Urban

Subjects
Adult, Hepatitis B virus, Hepatitis D, Chronic, Coinfection, Adenine, Antiviral Agents, Hepatitis D, Infectious Diseases, Hepatitis B, Chronic, Treatment Outcome, Humans, RNA, Hepatitis Delta Virus, Tenofovir
Abstract

Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing authorisation by the European Medical Agency for treatment of chronic hepatitis D virus infection. We investigated the antiviral activity of bulevirtide in patients chronically infected with HBV and hepatitis D virus.MYR202 (ClinicalTrials.gov, NCT03546621; EudraCT, 2016-000395-13) was a multicentre, parallel-group, randomised, open-label, phase 2 trial. Adults (aged 18-65 years) with chronic hepatitis D virus infection, including patients with cirrhosis and patients who had contraindications to PegIFNα treatment or for whom treatment did not work, were eligible and were enrolled from four hospitals in Germany and 12 hospitals in Russia. Patients were randomly assigned (1:1:1:1) to receive 2 mg (n=28), 5 mg (n=32), or 10 mg (n=30) subcutaneous bulevirtide once per day with tenofovir disoproxil fumarate (TDF; 245 mg once per day orally) or TDF alone (245 mg once per day orally; n=30) for 24 weeks. Randomisation was done using a digital block scheme with stratification, consisting of 480 randomisation numbers separated into 30 blocks. The primary endpoint was undetectable hepatitis D virus RNA or 2 logBetween Feb 16, 2016, and Dec 8, 2016, 171 patients with chronic hepatitis D virus infection were screened; 51 were ineligible based on the exclusion criteria and 120 patients (59 with cirrhosis) were enrolled. At week 24, 15 (54%, 95% CI 34-73) of 28 patients achieved undetectable hepatitis D virus RNA or a 2 logBulevirtide induced a significant decline in hepatitis D virus RNA over 24 weeks. After cessation of bulevirtide, hepatitis D virus RNA concentrations rebounded. Longer treatment durations and combination therapies should be investigated.Hepatera LLC, MYR GmbH, and the German Centre for Infection Research, TTU Hepatitis.

Published
2021

8. Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

Author

Pietro Lampertico, Soo Aleman, Antje Blank, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Morozov Viacheslav, Olga Sagalova, Tatyana Stepanova, Vithika Suri, Dmitry Manuilov, Lei Ye, John F. Flaherty, Anu Osinusi, Markus Cornberg, Maurizia Brunetto, and Heiner Wedemeyer

Subjects
Hepatology
Published
2022
Full Text
View/download PDF

9. Double Refinement Network for Efficient Indoor Monocular Depth Estimation

Author

Nikita Durasov, Valeriya Bubnova, Anton Konushin, Pavel Bogomolov, and Mikhail Romanov

Subjects
FOS: Computer and information sciences, Speedup, Monocular, Artificial neural network, Pixel, Computer science, Computer Vision and Pattern Recognition (cs.CV), Process (computing), Computer Science - Computer Vision and Pattern Recognition, ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION, 02 engineering and technology, 010501 environmental sciences, Frame rate, 01 natural sciences, 0202 electrical engineering, electronic engineering, information engineering, Benchmark (computing), RGB color model, 020201 artificial intelligence & image processing, Algorithm, 0105 earth and related environmental sciences
Abstract

Monocular depth estimation is the task of obtaining a measure of distance for each pixel using a single image. It is an important problem in computer vision and is usually solved using neural networks. Though recent works in this area have shown significant improvement in accuracy, the state-of-the-art methods tend to require massive amounts of memory and time to process an image. The main purpose of this work is to improve the performance of the latest solutions with no decrease in accuracy. To this end, we introduce the Double Refinement Network architecture. The proposed method achieves state-of-the-art results on the standard benchmark RGB-D dataset NYU Depth v2, while its frames per second rate is significantly higher (up to 18 times speedup per image at batch size 1) and the RAM usage per image is lower.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results